See more : SecUR Credentials Limited (SECURCRED.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Knight Therapeutics Inc. (KHTRF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Knight Therapeutics Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- InNature Berhad (5295.KL) Income Statement Analysis – Financial Results
- Ameren Illinois Company (AILLN) Income Statement Analysis – Financial Results
- Zhejiang Truelove Vogue Co., Ltd. (003041.SZ) Income Statement Analysis – Financial Results
- Kavveri Telecom Products Limited (KAVVERITEL.NS) Income Statement Analysis – Financial Results
- Sabana Industrial Real Estate Investment Trust (M1GU.SI) Income Statement Analysis – Financial Results
Knight Therapeutics Inc. (KHTRF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.gud-knight.com
About Knight Therapeutics Inc.
Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib to treat metastatic cholangiocarcinoma; Trelstar for advanced prostate cancer and for pain associated with endometriosis; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven for metastatic breast cancer and doft tissue sarcoma; and Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma. The company also provides Ladevina for multiple myeloma, myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Exelon for mild to moderately severe dementia; and Ibsrela for the treatment of irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk to treat biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms associated with menopause in women with intact uteri; Fibridoner to treat idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection in patients with cystic fibrosis; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, the company finances other life science companies; and invests in life sciences venture capital funds. Knight Therapeutics Inc. was incorporated in 2013 and is headquartered in Montreal, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 328.20M | 293.56M | 243.48M | 199.52M | 47.46M | 12.50M | 8.63M | 5.94M | 1.04M | 365.32K | 0.00 |
| Cost of Revenue | 175.55M | 155.50M | 128.07M | 117.83M | 20.54M | 2.31M | 1.59M | 1.55M | 428.00K | 0.00 | 0.00 |
| Gross Profit | 152.65M | 138.06M | 115.41M | 81.69M | 26.92M | 10.20M | 7.05M | 4.39M | 609.00K | 365.32K | 0.00 |
| Gross Profit Ratio | 46.51% | 47.03% | 47.40% | 40.94% | 56.72% | 81.56% | 81.64% | 73.91% | 58.73% | 100.00% | 0.00% |
| Research & Development | 17.55M | 14.76M | 12.69M | 11.73M | 3.91M | 1.99M | 2.75M | 1.96M | 2.71M | 1.03M | 0.00 |
| General & Administrative | 37.41M | 40.15M | 37.16M | 38.85M | 24.46M | 8.47M | 8.20M | 9.30M | 9.09M | 4.28M | 0.00 |
| Selling & Marketing | 46.28M | 48.47M | 37.22M | 35.59M | 7.79M | 3.59M | 3.38M | 532.00K | 0.00 | 0.00 | 0.00 |
| SG&A | 83.69M | 88.62M | 74.38M | 74.43M | 32.25M | 12.06M | 11.58M | 9.83M | 9.09M | 4.28M | 0.00 |
| Other Expenses | 54.30M | 51.74M | 41.18M | 25.54M | 3.41M | 1.98M | 1.53M | 3.89M | 2.86M | 435.39K | 0.00 |
| Operating Expenses | 155.54M | 155.12M | 128.24M | 111.69M | 39.58M | 15.98M | 15.96M | 12.23M | 11.92M | 5.40M | 0.00 |
| Cost & Expenses | 331.09M | 310.62M | 256.31M | 229.52M | 60.12M | 18.28M | 17.54M | 13.78M | 12.35M | 5.40M | 0.00 |
| Interest Income | 12.58M | 10.63M | 7.38M | 14.32M | 23.54M | 20.93M | 26.30M | 24.41M | 18.63M | 3.90M | 0.00 |
| Interest Expense | 12.49M | 6.60M | 3.62M | 3.40M | 1.01M | 0.00 | 0.00 | 0.00 | 0.00 | 23.54K | 0.00 |
| Depreciation & Amortization | 50.40M | 62.62M | 47.92M | 32.08M | 4.27M | 1.93M | 1.63M | 437.00K | 124.00K | 85.19K | 0.00 |
| EBITDA | 40.90M | 25.26M | 42.59M | 28.64M | 27.42M | -3.85M | -7.28M | -7.40M | -11.18M | -4.95M | 0.00 |
| EBITDA Ratio | 12.46% | 20.51% | 17.49% | 14.35% | 38.47% | -125.04% | -100.78% | -128.06% | 1,094.41% | -167.35% | 0.00% |
| Operating Income | -2.89M | -2.40M | -5.32M | -3.44M | 13.99M | -17.56M | -10.33M | -8.04M | 11.23M | -696.57K | 0.00 |
| Operating Income Ratio | -0.88% | -0.82% | -2.19% | -1.72% | 29.47% | -140.50% | -119.64% | -135.42% | 1,082.45% | -190.67% | 0.00% |
| Total Other Income/Expenses | -19.10M | -2.92M | 19.52M | 62.74M | 39.67M | 35.25M | 30.11M | 31.31M | 48.20M | 136.09M | 0.00 |
| Income Before Tax | -21.99M | -43.96M | 6.69M | 32.09M | 22.78M | 29.46M | 21.20M | 23.47M | 37.02M | 131.05M | 0.00 |
| Income Before Tax Ratio | -6.70% | -14.97% | 2.75% | 16.08% | 48.00% | 235.71% | 245.53% | 395.17% | 3,569.53% | 35,873.36% | 0.00% |
| Income Tax Expense | -5.15M | -14.07M | -8.99M | 325.00K | 4.75M | 5.39M | 3.96M | 4.91M | 2.85M | 5.19M | 0.00 |
| Net Income | -16.84M | -29.89M | 15.68M | 31.76M | 14.52M | 24.08M | 17.24M | 18.56M | 34.17M | 125.86M | 0.00 |
| Net Income Ratio | -5.13% | -10.18% | 6.44% | 15.92% | 30.59% | 192.63% | 199.72% | 312.46% | 3,294.79% | 34,451.40% | 0.00% |
| EPS | -0.16 | -0.26 | 0.13 | 0.24 | 0.10 | 0.17 | 0.12 | 0.15 | 0.36 | 2.20 | 0.00 |
| EPS Diluted | -0.16 | -0.26 | 0.13 | 0.24 | 0.10 | 0.17 | 0.12 | 0.15 | 0.35 | 2.20 | 0.00 |
| Weighted Avg Shares Out | 107.47M | 114.89M | 124.48M | 131.78M | 139.76M | 142.83M | 142.76M | 120.72M | 96.19M | 57.25M | 0.00 |
| Weighted Avg Shares Out (Dil) | 107.47M | 114.89M | 124.52M | 131.99M | 140.14M | 143.28M | 143.42M | 121.26M | 96.53M | 57.30M | 0.00 |
Knight Therapeutics Inc. (KHTRF) Q3 2024 Earnings Call Transcript
Knight Therapeutics Reports Third Quarter 2024
Notice of Knight Therapeutics' Third Quarter 2024 Results Conference Call
Knight Therapeutics Inc. places No. 397 on The Globe and Mail's sixth annual ranking of Canada's Top Growing Companies
Knight Therapeutics Reports Second Quarter 2024
Notice of Knight Therapeutics' Second Quarter 2024 Results Conference Call
Knight Therapeutics, Inc. (KHTRF) Q1 2024 Earnings Call Transcript
Knight Therapeutics Reports First Quarter 2024 Results
Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Ironshore Pharmaceuticals & Development, Inc. for JORNAY PM® for Canada and Latin America
Knight Therapeutics Inc. announces voting results from the Annual General Meeting
Source: https://incomestatements.info
Category: Stock Reports